NRG GU007

Primary Category:

Radiation Oncology

Disease Category:

Genitourinary, Prostate

Status:

Open

Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen DeprIvation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (with Initial Phase I)

NCT#04037254

GU007 is reopened to accrual to phase I/dose level 3, effective September 26, 2022.

GU007 Phase II is not open to accrual as of January 27, 2022.